CPIX · Cumberland Pharmaceuticals Inc
$7.65
+0.15 (+2.00%)
At close · Aug 21
Market Cap
$114.62M
Shares
14.98M
Cumberland Pharmaceuticals Inc Earnings Call Transcripts
Every quarterly earnings call for Cumberland Pharmaceuticals Inc (CPIX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲41.4%
$11.41M
−$408,639
'22 Q3
22-11-08
▲9.7%
$9.12M
−$2.44M
'22 Q4
23-03-07
▼17.5%
$9.22M
$192,184
'23 Q1
23-05-09
▲5.7%
$10.89M
$872,200
'23 Q2
23-08-08
▼11.6%
$10.09M
−$1.05M
'23 Q3
23-11-07
▲2.5%
$9.35M
−$6.29M
'23 Q4
24-03-05
▼7.9%
$8.50M
−$1.95M
'24 Q1
24-05-07
▼9.6%
$9.85M
−$1.09M
'24 Q2
24-08-06
▼9.9%
$9.09M
−$1.54M
'24 Q3
24-11-07
▲11.6%
$10.44M
−$1.90M
'24 Q4
25-03-04
▲37.8%
$11.71M
$1.26M
'25 Q1
25-05-06
▼96.1%
$380,797
−$740,740
'25 Q2
25-08-05
▼8.7%
$8.29M
−$1.94M
'25 Q3
25-11-04
▲31.1%
$13.68M
−$1.41M
'25 Q4
26-03-03
▼22%
$9.13M
−$3.29M
'26 Q1
26-05-05
LATEST
▼56.3%
$166,458
−$4.28M
'26 Q2
26-08-04
Earnings call
FY26 · Q2
2026-08-04
Cumberland Pharmaceuticals Inc Q2 FY2026 Earnings Call
Confident tone
Strategic Transaction with Apotex
FDA Regulatory Engagement and Designations
Duchenne Muscular Dystrophy Program
Revenue
$166,458
▼ 56.3% YoY Diluted EPS
$-0.29
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-05
Cumberland Pharmaceuticals Inc Q1 FY2026 Earnings Call
Confident tone
Caldolor label expansion
Strategic transaction with Apotex
Talicia commercialization
Revenue
$9.13M
▼ 22% YoY Diluted EPS
$-0.22
▼ 375% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Cumberland Pharmaceuticals Inc Q4 FY2025 Earnings Call
Positive tone
Revenue growth and product portfolio
Clinical pipeline and DMD program
Operating expenses and net loss
Revenue
$13.68M
▲ 31.1% YoY Diluted EPS
$-0.09
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Cumberland Pharmaceuticals Inc Q3 FY2025 Earnings Call
Confident tone
Portfolio brand performance and sales organization
International expansion
Ifetroban clinical pipeline
Revenue
$8.29M
▼ 8.7% YoY Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Cumberland Pharmaceuticals Inc Q2 FY2025 Earnings Call
Confident tone
Vibativ antibiotic franchise
Ifetroban clinical pipeline
Marketed brand portfolio performance
Revenue
$380,797
▼ 96.1% YoY Diluted EPS
$-0.05
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Cumberland Pharmaceuticals Inc Q1 FY2025 Earnings Call
Confident tone
Brand portfolio performance
DMD clinical program (ifetroban)
Vibativ antibiotic
Revenue
$11.71M
▲ 37.8% YoY Diluted EPS
$0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Cumberland Pharmaceuticals Inc Q4 FY2024 Earnings Call
Confident tone
Ifetroban / Duchenne Muscular Dystrophy clinical program
Vibativ antibiotic growth and international expansion
Caldolor product evidence and FDA updates
Revenue
$10.44M
▲ 11.6% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Cumberland Pharmaceuticals Inc Q3 FY2024 Earnings Call
Positive tone
Brand portfolio performance
International expansion and partnerships
Medicaid coverage expansion for Kristalose
Revenue
$9.09M
▼ 9.9% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Cumberland Pharmaceuticals Inc Q2 FY2024 Earnings Call
Positive tone
Vibativ product and pipeline
Kristalose commercial updates
Caldolor and NOPAIN Act
Revenue
$9.85M
▼ 9.6% YoY Diluted EPS
$-0.08
▼ 233.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Cumberland Pharmaceuticals Inc Q1 FY2024 Earnings Call
Positive tone
Caldolor growth and NOPAIN Act
Vibativ brand updates and international expansion
Kristalose Medicaid coverage
Revenue
$8.50M
▼ 7.9% YoY Diluted EPS
$-0.14
▼ 1500% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-05
Cumberland Pharmaceuticals Inc Q4 FY2023 Earnings Call
Positive tone
Brand performance and revenue
Caldolor pediatric labeling and No Pain Act
International expansion of Vibativ
Revenue
$9.35M
▲ 2.5% YoY Diluted EPS
$-0.44
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Cumberland Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$10.09M
▼ 11.6% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Cumberland Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$10.89M
▲ 5.7% YoY Diluted EPS
$0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Cumberland Pharmaceuticals Inc Q1 FY2023 Earnings Call
Revenue
$9.22M
▼ 17.5% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Cumberland Pharmaceuticals Inc Q4 FY2022 Earnings Call
Revenue
$9.12M
▲ 9.7% YoY Diluted EPS
$-0.17
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Cumberland Pharmaceuticals Inc Q3 FY2022 Earnings Call
Revenue
$11.41M
▲ 41.4% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Cumberland Pharmaceuticals Inc Q2 FY2022 Earnings Call
Revenue
$10.30M
▲ 13.7% YoY Diluted EPS
$-0.09
▼ 212.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Cumberland Pharmaceuticals Inc Q1 FY2022 Earnings Call
Revenue
$11.18M
▲ 6.1% YoY Diluted EPS
$-0.09
▼ 1000% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Cumberland Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$8.32M
▼ 18.9% YoY Diluted EPS
$-0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Cumberland Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$8.07M
▼ 12.7% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Cumberland Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$9.06M
▼ 5.7% YoY Diluted EPS
$0.08
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-11
Cumberland Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$10.54M
▲ 26.5% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Cumberland Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$10.26M
▲ 10.3% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Cumberland Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$9.25M
▲ 33.4% YoY Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
Cumberland Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$9.60M
▲ 1.9% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-20
Cumberland Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$8.33M
▼ 4.6% YoY Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-18
Cumberland Pharmaceuticals Inc Q4 FY2019 Earnings Call
Revenue
$9.31M
▼ 31.1% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–27 of 27 earnings calls
Key facts
CIK
1087294
CUSIP
230770109
13F (30d)
32 filings
32 filers
Visit website
Investor relations